Novo Nordisk is permanently discontinuing the manufacture and distribution of GlucaGen® HypoKit® in the U.S. on July 1, 2024.
This is due to an ongoing global shortfall of pre-filled syringes from an external vendor. In the U.S. market, alternative hypoglycemia rescue medications are available and therefore Novo Nordisk has made the decision to prioritize supply of GlucaGen® HypoKit® in markets around the world that have no alternative treatment options.
Our top priority is always the health and safety of the patients that use our products. We made this decision after careful consideration given that patients will be able to access alternative treatments in the U.S.
We will continue to provide GlucaGen® HypoKit® to wholesalers while supplies last until July 1, 2024.
To minimize the impact of this decision on the diabetes community, we are making healthcare providers, wholesalers, and payers aware of the discontinuation more than six months in advance so they can enable smooth transitions to other options.
In advance of this upcoming discontinuation, we recommend that healthcare providers proactively talk to their patients about alternative treatment options to ensure continuity of care.